FDA Approves New CRISPR Gene-Editing Treatment
The FDA approved Casgevy, a CRISPR-based therapy by Vertex Pharmaceuticals and CRISPR Therapeutics, for treating transfusion-dependent beta thalassemia, following its approval for sickle cell disease. Casgevy modifies patients' blood cells to increase hemoglobin production, with common side effects including mouth sores and fever. Vertex is establishing treatment centers across the U.S. for its administration.
Reference News
The FDA approved Casgevy, a CRISPR-based therapy by Vertex Pharmaceuticals and CRISPR Therapeutics, for treating transfusion-dependent beta thalassemia, following its approval for sickle cell disease. Casgevy modifies patients' blood cells to increase hemoglobin production, with common side effects including mouth sores and fever. Vertex is establishing treatment centers across the U.S. for its administration.